ERROR2: Endometrioma Per se Versus Treatment Related Reduction in Ovarian Reserve (ERROR-2 Trial)

Sponsor
Uludag University (Other)
Overall Status
Unknown status
CT.gov ID
NCT03620838
Collaborator
(none)
250
1
18.1
13.8

Study Details

Study Description

Brief Summary

The present multi-center study aimed to evaluate whether endometrioma-associated decline in ovarian reserve is progressive in the absence of an intervention and is greater in magnitude than the natural decline over time. Also the affect of endometrioma treatment modalities like surgery or medical on the ovarian reserve over time.

Condition or Disease Intervention/Treatment Phase
  • Drug: oral contraceptive pill, oral progesterone

Detailed Description

While there is now a proven, prominent relationship between endometriosis and infertility, the exact mechanism of this relationship is still unclear. The relationship between endometriosis and infertility has been increasingly investigated in recent years. Infertility can be explained in those patients with advanced disease, which causes disturbance of the pelvic anatomy and will also prevent tubal passage, but the mechanism at the early stage of endometriosis has not yet been elucidated.

It has been shown that patients with endometriomas have low quantitative ovarian-reserve tests. It has also been shown with oocyte donation studies that endometriosis may be accompanied by a quantitative decrease in oocyte quality defects which may further adversely affect existing ovarian reserves. There are still debates as to whether the presence of endometriomas and the availability of endometriomas itself reduces the over-reserve, but there is no objective study or data on the subject.There are a number of studies that endometriosis may negatively affect the reserve, and also that surgery may cause further damage to the ovarian reserve.There is still lack of definite data for the affect of endometriomas per se and endometriomas treatment modalities ( Oral contraceptive pills (OCP) / progesterone or surgery)on the ovarian reserve over time. For this reason the investigators aimed to evaluate whether endometrioma-associated decline in ovarian reserve is progressive in the absence of any intervention and is greater in magnitude than the natural decline over time. Also the affect of endometrioma treatment modalities like surgery or medical on the ovarian reserve over time.

The study is planned as a prospective study including women with endometrioma diagnosed with ultrasonography and also healthy age matched women without endometriomas as the control group. Endometrioma patients will be divided to 4 subgroups of patients. The first group will be comprised women with endometriomas that who will not require any medical or surgical intervention, the second subgroup will be comprised from endometrioma patients will be treated with OCP during the study period, the third one will be comprised from endometrioma patients will be treated with progesterone and the last subgroup will be comprised from endometrioma patients who will be treated with surgical excision of the cyst. All of the patients with and without endometrioma will be evaluated with ultrasonography for Antral Follicle Count (AFC) and blood samples will be taken during recruitment for Anti-müllerian Hormone (AMH) values. Additional assessments will be done after 3 and 6 months after the first assessment. All the results will be statistically compared within the groups.

Study Design

Study Type:
Observational
Anticipated Enrollment :
250 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Endometrioma Per se Versus Treatment Related Reduction in Ovarian Reserve (ERROR-2 Trial)
Actual Study Start Date :
Mar 1, 2019
Anticipated Primary Completion Date :
Sep 1, 2020
Anticipated Study Completion Date :
Sep 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Group 1

Patients with endometrioma who had at least one endometrioma >3 cm and who will not need hormonal or surgical treatment at the time of diagnosis and who will be expectantly managed

Group 2

Patients with endometrioma who had at least one endometrioma >3 cm and who will be treated with OCP during the study period

Drug: oral contraceptive pill, oral progesterone
ovarian endometrioma cyst excision
Other Names:
  • surgery
  • Group 3

    Patients with endometrioma who had at least one endometrioma >3 cm and who will be treated with oral progesterone during the study period

    Drug: oral contraceptive pill, oral progesterone
    ovarian endometrioma cyst excision
    Other Names:
  • surgery
  • Group 4

    Patients with endometrioma who had at least one endometrioma >3 cm and who will be treated with surgery short after recruitment

    Drug: oral contraceptive pill, oral progesterone
    ovarian endometrioma cyst excision
    Other Names:
  • surgery
  • Group 5

    The control group, who do not have endometrioma and any gynecological disorder

    Outcome Measures

    Primary Outcome Measures

    1. AMH [6 months]

      Change from baseline Anti müllerian hormone levels at 6 months

    Secondary Outcome Measures

    1. AFC [6 months]

      Change from baseline Antral follicule counts at 6 months

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 40 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Women between 18 and 40 years of age

    • Who had at least one endometrioma >3 cm

    Exclusion Criteria:
    • İrregular periods

    • Polycystic ovarian syndrome

    • Pregnant patients

    • Patients unable to give informed consent • Using medication which could affect ovarian function during six months before recruitment

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Uludag University Scholl of medicine Bursa Turkey/bursa Turkey

    Sponsors and Collaborators

    • Uludag University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    GÜRKAN UNCU,PROF. MD, Principal Investigator ; Prof. Dr. Gürkan Uncu, Uludag University
    ClinicalTrials.gov Identifier:
    NCT03620838
    Other Study ID Numbers:
    • Uludag University
    First Posted:
    Aug 8, 2018
    Last Update Posted:
    Oct 10, 2019
    Last Verified:
    Oct 1, 2019
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 10, 2019